
Matthias J. MÃ¹/₄ller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6021462/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ultrastructural Hippocampal and White Matter Alterations in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study. Dementia and Geriatric Cognitive Disorders, 2004, 18, 101-108.	0.7	272
2	Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiology of Aging, 2005, 26, 1193-1198.	1.5	253
3	Differentiating moderate and severe depression using the Montgomery–Åsberg depression rating scale (MADRS). Journal of Affective Disorders, 2003, 77, 255-260.	2.0	210
4	Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. NeuroImage, 2005, 28, 1033-1042.	2.1	181
5	CNS manifestations of Fabry's disease. Lancet Neurology, The, 2006, 5, 791-795.	4.9	172
6	Early Improvement Under Mirtazapine and Paroxetine Predicts Later Stable Response and Remission With High Sensitivity in Patients With Major Depression. Journal of Clinical Psychiatry, 2003, 64, 413-420.	1.1	160
7	Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiology of Aging, 2007, 28, 398-403.	1.5	130
8	Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Research - Neuroimaging, 2006, 146, 283-287.	0.9	113
9	Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo. Neuropsychopharmacology, 2003, 28, 787-794.	2.8	105
10	Therapeutic Monitoring of New Antipsychotic Drugs. Therapeutic Drug Monitoring, 2004, 26, 156-160.	1.0	105
11	Moderate and severe depression. Journal of Affective Disorders, 2000, 60, 137-140.	2.0	97
12	Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World Journal of Biological Psychiatry, 2008, 9, 212-218.	1.3	97
13	Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome. Journal of Clinical Psychopharmacology, 1998, 18, 111-120.	0.7	93
14	Functional relevant loss of long association fibre tracts integrity in early Alzheimer's disease. Neuropsychologia, 2008, 46, 1698-1706.	0.7	90
15	Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. NeuroImage, 2006, 30, 1332-1339.	2.1	71
16	Can delusions be self-assessed? Concordance between self- and observer-rated delusions in schizophrenia. Psychiatry Research, 2010, 178, 249-254.	1.7	70
17	The Calgary Depression Rating Scale for Schizophrenia: development and interrater reliability of a German version (CDSS-G). Journal of Psychiatric Research, 1999, 33, 433-443.	1.5	69
18	Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology, 2006, 31, 256-264.	1.3	68

Matthias J. Müller

#	Article	IF	CITATIONS
19	Therapeutic Monitoring of Aripiprazole by HPLC with Column-Switching and Spectrophotometric Detection. Clinical Chemistry, 2005, 51, 1718-1721.	1.5	67
20	Standardized rater training for the Hamilton Depression Rating Scale (HAMD-17) in psychiatric novices. Journal of Affective Disorders, 2003, 77, 65-69.	2.0	62
21	TheMAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 325-331.	1.1	57
22	Effects of Interrater Reliability of Psychopathologic Assessment on Power and Sample Size Calculations in Clinical Trials. Journal of Clinical Psychopharmacology, 2002, 22, 318-325.	0.7	52
23	Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia. Journal of Psychiatric Research, 2007, 41, 673-679.	1.5	51
24	Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World Journal of Biological Psychiatry, 2007, 8, 123-126.	1.3	49
25	FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Research - Neuroimaging, 2007, 155, 167-171.	0.9	48
26	Late structural alterations of cerebral white matter in longâ€ŧerm survivors of childhood leukemia. Journal of Magnetic Resonance Imaging, 2008, 27, 1250-1255.	1.9	48
27	Cost and Care of Patients with Alzheimer's Disease: Clinical Predictors in German Health Care Settings. Journal of Alzheimer's Disease, 2011, 27, 723-736.	1.2	48
28	Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research, 1998, 32, 151-160.	1.1	46
29	Pattern of microstructural brain tissue alterations in Fabry disease. Journal of Neurology, 2006, 253, 780-787.	1.8	46
30	Association of elevated phospho-tau levels with alzheimer-typical 18F-Fluoro-2-Deoxy-D-Glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry, 2004, 56, 279-283.	0.7	45
31	Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophrenia Research, 2001, 49, 223-225.	1.1	38
32	Functional implications of hippocampal degeneration in early Alzheimer's disease: a combined DTI and PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2219-2227.	3.3	38
33	Patients' satisfaction with psychiatric treatment: comparison between an open and a closed ward. Psychiatric Quarterly, 2002, 73, 93-107.	1.1	36
34	Mortality in affective disorders. Journal of Affective Disorders, 2001, 65, 263-274.	2.0	35
35	Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression. Journal of Clinical Psychopharmacology, 2011, 31, 281-286.	0.7	33
36	Symptom-Triggered versus Standard Chlormethiazole Treatment of Inpatient Alcohol Withdrawal: Clinical Implications from a Chart Analysis, European Addiction Research, 2003, 9, 1-7	1.3	32

3

#	Article	IF	CITATIONS
37	Validating the DemTect with 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography as a Sensitive Neuropsychological Screening Test for Early Alzheimer Disease in Patients of a Memory Clinic. Dementia and Geriatric Cognitive Disorders, 2005, 20, 271-277.	0.7	32
38	Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales. Canadian Journal of Psychiatry, 2006, 51, 387-392.	0.9	31
39	Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil. Journal of Affective Disorders, 2001, 66, 255-261.	2.0	30
40	The Calgary Depression Rating Scale for schizophrenia in a healthy control group: Psychometric properties and reference values. Journal of Affective Disorders, 2005, 88, 69-74.	2.0	30
41	Helplessness and perceived pain intensity: relations to cortisol concentrations after electrocutaneous stimulation in healthy young men. BioPsychoSocial Medicine, 2011, 5, 8.	0.9	30
42	Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). Journal of Psychiatric Research, 1998, 32, 369-378.	1.5	29
43	Increased hippocampal head diffusivity predicts impaired episodic memory performance in early Alzheimer's disease. Neuropsychologia, 2010, 48, 1447-1453.	0.7	29
44	Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram. Therapeutic Drug Monitoring, 2013, 35, 396-401.	1.0	29
45	Combination Treatment With Nefazodone and Cognitive-Behavioral Therapy for Relapse Prevention in Alcohol-Dependent Men. Journal of Clinical Psychiatry, 2004, 65, 1406-1413.	1.1	29
46	CSF APPsα and Phosphorylated Tau Protein Levels in Mild Cognitive Impairment and Dementia of Alzheimer's Type. Journal of Geriatric Psychiatry and Neurology, 2009, 22, 3-9.	1.2	28
47	Will it hurt less if I believe I can control it? Influence of actual and perceived control on perceived pain intensity in healthy male individuals: a randomized controlled study. Journal of Behavioral Medicine, 2012, 35, 529-537.	1.1	28
48	Hyperintentionality during automatic perception of naturalistic cooperative behavior in patients with schizophrenia. Social Neuroscience, 2013, 8, 489-504.	0.7	28
49	Dysconnectivity of the inferior frontal gyrus: Implications for an impaired self-other distinction in patients with schizophrenia. Psychiatry Research - Neuroimaging, 2014, 223, 202-209.	0.9	28
50	Dose-Related Effects of Amisulpride on Five Dimensions of Psychopathology in Patients With Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology, 2002, 22, 554-560.	0.7	26
51	Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. Journal of Inherited Metabolic Disease, 2012, 35, 363-367.	1.7	25
52	No Association Between the Dopamine D2 Receptor Taq I A1 Allele and Earlier Age of Onset of Alcohol Dependence According to Different Specified Criteria. Alcoholism: Clinical and Experimental Research, 2001, 25, 805-809.	1.4	23
53	Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Journal of Psychopharmacology, 2009, 23, 278-286.	2.0	23
54	A monoamine oxidase B gene variant and short-term antidepressant treatment response. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1370-1377.	2.5	22

#	Article	IF	CITATIONS
55	Relapse (Number of Detoxifications) in Abstinent Male Alcohol-Dependent Patients as Related to Personality Traits and Types of Tolerance to Frustration. Neuropsychobiology, 2013, 67, 241-248.	0.9	22
56	Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample. Journal of Sleep Research, 2002, 11, 179-180.	1.7	21
57	Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1095-1100.	2.5	21
58	Quantification of brain tissue alterations in Fabry disease using diffusionâ€ŧensor imaging. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 33-36.	0.7	20
59	Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology, 1999, 146, 81-86.	1.5	19
60	Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Research, 1999, 89, 275-280.	1.7	19
61	Relationships between hippocampal microstructure, metabolism, and function in early Alzheimer's disease. Brain Structure and Function, 2011, 216, 219-226.	1.2	19
62	Revisiting the Ehlers and Kupfer hypothesis: The growth hormone cortisol secretion ratio during sleep is correlated with electroencephalographic slow wave activity in normal volunteers. Biological Psychiatry, 1996, 39, 139-142.	0.7	18
63	Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controlled diabetes mellitus. BMC Psychiatry, 2013. 13. 206.	1.1	18
64	Side effects of adjunct light therapy in patients with major depression. European Archives of Psychiatry and Clinical Neuroscience, 1997, 247, 252-258.	1.8	17
65	The "DGPPN-Cohort― a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 695-701.	1.8	17
66	Serial partial sleep deprivation as adjuvant treatment of depressive insomnia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 593-602.	2.5	16
67	Stage-Dependent Agreement between Cerebrospinal Fluid Proteins and FDG-PET Findings in Alzheimer's Disease. Current Alzheimer Research, 2012, 9, 241-247.	0.7	16
68	Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects. Journal of Psychiatric Research, 1997, 31, 543-554.	1.5	15
69	Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. Schizophrenia Research, 2002, 57, 307-309.	1.1	15
70	Cognitive behavioural therapy in elderly type 2 diabetes patients with minor depression or mild major depression: study protocol of a randomized controlled trial (MIND-DIA). BMC Geriatrics, 2010, 10, 21.	1.1	15
71	Preventing COVID-19 outbreaks through surveillance testing in healthcare facilities: a modelling study. BMC Infectious Diseases, 2022, 22, 105.	1.3	13
72	Three dimensions of depression in patients with acute psychotic disorders: A replication study. Comprehensive Psychiatry, 1999, 40, 449-457.	1.5	12

Matthias J. Müller

#	Article	IF	CITATIONS
73	Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. International Clinical Psychopharmacology, 2004, 19, 325-330.	0.9	12
74	Evening preference and poor sleep independently affect attentional-executive functions in patients with depression. Psychiatry Research, 2019, 281, 112533.	1.7	12
75	Salivary Testosterone and Simple Reaction Time Parameters. Neuropsychobiology, 1994, 30, 173-177.	0.9	11
76	Implicit attributional style revisited: Evidence for a state-specific "self-decreasing―implicit attributional style in patients with persecutory delusions. Cognitive Neuropsychiatry, 2010, 15, 451-476.	0.7	11
77	Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides, 1995, 16, 1475-1481.	1.2	10
78	Prescription of Benzodiazepines and Related Drugs in Patients with Mild Cognitive Deficits and Alzheimer's Disease. Pharmacopsychiatry, 2019, 52, 84-91.	1.7	10
79	Cost-effectiveness analysis of cognitive behaviour therapy for treatment of minor or mild-major depression in elderly patients with type 2 diabetes: study protocol for the economic evaluation alongside the MIND-DIA randomized controlled trial (MIND-DIA CEA). BMC Geriatrics, 2009, 9, 25.	1.1	9
80	Influence of chronotype on daily mood fluctuations: pilot study in patients with depression. BJPsych Open, 2020, 6, e17.	0.3	9
81	Relationship of Psychiatric Experience and Interrater Reliability in Assessment of Negative Symptoms. Journal of Nervous and Mental Disease, 1999, 187, 316-318.	0.5	9
82	Cerebrospinal Fluid Tau Protein Levels and ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2010, 30, 245-253.	0.7	8
83	Syndrome profiles in alcoholism and panic disorder with or without agoraphobia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2002, 26, 1079-1087.	2.5	7
84	Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis. European Psychiatry, 2003, 18, 318-319.	0.1	7
85	Recurrent brief depression in a female patient with Fabry disease. Bipolar Disorders, 2006, 8, 418-419.	1.1	7
86	Catecholamine Response Curves of Male Hypertensives Identified by Lehmacher's Two Sample Configural Frequency Analysis. Biometrical Journal, 1997, 39, 29-38.	0.6	6
87	Perceived Discrimination in Patients With Psychiatric Disorder and Turkish Migration Background in Germany. Journal of Nervous and Mental Disease, 2016, 204, 542-546.	0.5	5
88	SEQUENTIALLY ADJUSTED RANDOMIZATION TO FORCE BALANCE IN CONTROLLED TRIALS WITH UNKNOWN PREVALENCE OF COVARIATES: APPLICATION TO ALCOHOLISM RESEARCH. Alcohol and Alcoholism, 2005, 40, 124-131.	0.9	4
89	Depressive Attribution Style and Stressor Uncontrollability Increase Perceived Pain Intensity after Electrical Skin Stimuli in Healthy Young Men. Pain Research and Management, 2013, 18, 203-206.	0.7	4
90	Carbohydrate-Deficient Transferrin (CDT) and HDL Cholesterol (HDL) Are Highly Correlated in Male Alcohol Dependent Patients. Alcoholism: Clinical and Experimental Research, 2000, 24, 497-500.	1.4	1

#	Article	IF	CITATIONS
91	Circadian preference and sleep quality in healthy controls and psychiatric inpatients with major depressive disorder – An actigraphy study incorporating morning and evening mood assessments. Chronobiology International, 2022, 39, 249-260.	0.9	1
92	Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia. Schizophrenia Research and Treatment, 2011, 2011, 1-7.	0.7	0